|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500111740 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-05 11:09:26 |
|
注册时间: Date of Registration: |
2025-11-05 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
中国哮喘数据登记暨在线管理平台建设项目 |
|
Public title: |
China Asthma Data Registry and Online Management Platform Construction Project |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国哮喘数据登记暨在线管理平台建设项目 |
|
Scientific title: |
China Asthma Data Registry and Online Management Platform Construction Project |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
易芳 |
研究负责人: |
赖克方 |
|
Applicant: |
Yi Fang |
Study leader: |
Lai Kefang |
|
申请注册联系人电话: Applicant telephone: |
+86 20 8156 6771 |
研究负责人电话: Study leader's telephone: |
+86 20 8156 6841 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
upyifang@163.com |
研究负责人电子邮件: Study leader's E-mail: |
klai@vip.163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市荔湾区桥中中路28号 |
研究负责人通讯地址: |
广东省广州市荔湾区桥中中路28号 |
|
Applicant address: |
No. 28, Qiaozhong Middle Road, Liwan District, Guangzhou City, Guangdong Province |
Study leader's address: |
No. 28, Qiaozhong Middle Road, Liwan District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
510000 |
研究负责人邮政编码: Study leader's postcode: |
510000 |
|
申请人所在单位: |
广州医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Guangzhou Medical University |
||
|
研究负责人所在单位: |
广州医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Guangzhou Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
医研伦审 2020 第113号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属第一医院科研项目审查伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-08-13 00:00:00 |
||
|
伦理委员会联系人: |
余达加 |
||
|
Contact Name of the ethic committee: |
Yu Dajia |
||
|
伦理委员会联系地址: |
广东省广州市荔湾区桥中中路28号 |
||
|
Contact Address of the ethic committee: |
No. 28, Qiaozhong Middle Road, Liwan District, Guangzhou City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8306 2938 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广州医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Guangzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市荔湾区桥中中路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 28, Qiaozhong Middle Road, Liwan District, Guangzhou City, Guangdong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
葛兰素史克(中国)投资有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
GlaxoSmithKline (China) Investment Co., Ltd. |
||||||||||||||||||||||
|
Target disease: |
Asthma |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
建立中国哮喘标准病例数据库及管理平台,基于该数据库观察国人哮喘相关临床特征、诊治现状及预后。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the clinical characteristics, management status quo, prognosis of asthma in China based on China Asthma Standard Case Database and Management Platform. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄5岁以上,体重>=15kg; 2.具有哮喘的临床症状和/或体征: (1)反复发作喘息、气急,伴或不伴胸闷或咳嗽,夜间及晨间多发,常与接触变应原、冷空气、物理、化学性刺激以及上呼吸道感染、运动等有关; (2)发作时双肺可闻及散在或弥漫性哮鸣音,呼气相延长; (3)上述症状和体征可经治疗缓解或自行缓解; 3.过去12个月内具备以下可变气流受限的客观检查的任一条: (1)支气管舒张试验阳性(吸入支气管舒张剂后,FEV1增加>12%,且FEV1绝对值增加>200ml); (2)支气管激发试验阳性; (3)呼气流量峰值(peakexpiratory flow, PEF)平均每日昼夜变异率(连续7d,每日PEF昼夜变异率之和/7)>10%,或PEF周变异率{(2周内最高PEF值一最低PEF值)/[(2周内最高PEF值+最低PEF)X 1/2]×100%}>20%。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age over 5 years, weight >=15 kg; 2. Presents clinical symptoms and/or signs of asthma: (1) Recurrent attacks of wheezing and shortness of breath, with or without chest tightness or cough, occurring mainly at night and in the morning, often related to exposure to allergens, cold air, physical or chemical stimuli, upper respiratory tract infections, exercise, etc.; (2) During attacks, scattered or diffuse wheezing can be heard in both lungs, with prolonged expiratory phase; (3) The above symptoms and signs can be relieved with treatment or resolve spontaneously; 3. Within the past 12 months, at least one of the following objective tests indicating variable airflow limitation: (1) Positive bronchodilator test (after inhalation of a bronchodilator, FEV1 increases by >12% and the absolute value of FEV1 increases by >200 ml); (2) Positive bronchial provocation test; (3) Peak expiratory flow (PEF) with an average daily diurnal variability rate (over 7 consecutive days, sum of daily PEF diurnal variability/7) >10%, or weekly PEF variability rate [(highest PEF value within 2 weeks - lowest PEF value within 2 weeks)/((highest PEF + lowest PEF)/2) × 100%] >20%. |
||||||||||||||||||||||
|
排除标准: |
无 |
||||||||||||||||||||||
|
Exclusion criteria: |
None |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2018-03-25 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-08-13 00:00:00 至 To 2028-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
邮件联系研究者 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Contact the researcher by email |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
eCRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |